Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

A Study to Understand the Analgesic Properties of Topically Applied Menthol When Used in a Marathon.

27. April 2026 aktualisiert von: Reckitt Benckiser Healthcare (UK) Limited

A Real-world Evidence Study to Understand the Analgesic Properties of Topically Applied Menthol When Used in a Marathon.

The purpose of the research study is to gather the opinions and/or perceptions relating to the use of topically applied menthol and experience of pain during and after a marathon in adult runners (18+ years) participating in the 2025 Chicago Marathon. The main questions it aims to answer are:

  • Does topically applied menthol reduce pain levels in marathon runners during recovery?
  • How quickly does pain relief occur after topically applied menthol application?
  • What are the sensory attributes (e.g., cooling sensation) associated with topically applied menthol use during and after the race?
  • How do demographic factors (e.g., age, sex, menstrual cycle stage, sleep quality) influence pain experience and topically applied menthol effectiveness?

Researchers will compare pre- and post-application pain scores in the Recovery Application Zone to see if Biofreeze provides measurable pain relief and sensory benefits.

Participants will:

  • Provide documented informed consent prior to participation.
  • Self-select to use Biofreeze products during or after the race.

  • Complete one or both of the following:

    1. Recovery Application Zone Questionnaire (includes pain score before and after Biofreeze application, sensory assessments, demographics).
    2. End of Race Questionnaire (includes retrospective recall of pain relief, product use, sensory experience, and demographic data).

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

This is a real-world, observational study evaluating self-selected use of topically applied menthol among runners in the 2025 Chicago Marathon.

Participants independently choose whether to use topically applied menthol products, which products to use, and how frequently to apply them as part of their usual pain-management behaviour.

The study does not assign or administer any intervention. Data are collected from participants who voluntarily used topically applied menthol and chose to complete the questionnaires.

Participants may self-select to use topically applied menthol products during the race or recovery as they normally would. Researchers do not assign or direct product use. Product application occurs independently of study participation.

Studientyp

Beobachtungs

Einschreibung (Tatsächlich)

367

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

  • Vereinigte Staaten
    • Illinois
      • Deerfield, Illinois, Vereinigte Staaten, 60015
        • Curion Strategic Product Insights

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Ja

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

This study will recruit runners over 18 years old, participating in the 2025 Chicago Marathon, capable of providing documented informed consent, who are not employees of Sponsor or the vendor collecting data.

Beschreibung

Inclusion Criteria:

  1. Participant has provided documented informed consent.
  2. Participant aged 18 years and above.
  3. Participant is entrant into the Chicago marathon 2025.
  4. Participant has self-selected to use topically applied menthol during the race or during immediate recovery.
  5. Comprehension of and able to read English.

Exclusion Criteria:

1. Employee of Sponsor or Agency/ vendor collecting the data

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

Kohorten und Interventionen

Gruppe / Kohorte
Intervention / Behandlung
Chicago Marathon Runners who use topically applied menthol
Sonstiges: Observational
Pain-experience observational study conducted during a marathon.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in Mean Pain Score
Zeitfenster: Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.
Pain relief was assessed by change in Numeric Rating Scale (NRS) 0-10 pre and post topical menthol application.
Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Proportion of participants reporting pain relief within 10 seconds after completed application of topically applied menthol.
Zeitfenster: Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.

Characterising the speed of analgesic effect from topically applied menthol in participants recovering from marathon.

Number of subjects whose pain score based on 0-10 NRS rating reduced from pre-application to post-application, whose post-application score was within 10 seconds.
Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.
Percentage of participants which report pain relief reduction of 2 points or greater on NRS within 10 seconds of topically applied menthol application.
Zeitfenster: Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.

Characterising the speed of analgesic effect from topically applied menthol in participants recovering from marathon.

Number of subjects whose pain score based on 0-10 Numerical Rating Scale rating reduced over 2 points from pre-application to post- application, whose post-application score was reported within 10 seconds.
Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.
Percentage of participants reporting a cooling sensation within 10 seconds/ immediately after application.
Zeitfenster: Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.
Percentage of participants reporting a cooling sensation within 10 seconds or immediately after application. Participants reported if they experienced a cooling sensation (YES/ NO) and for the next question, reported if that occurred within 10 seconds / immediately after application or over 10 seconds.
Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.
Percentage of participants experiencing cooling sensation lasting 2 hours or more after topically applied menthol use
Zeitfenster: Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.

Percentage of participants experiencing cooling sensation lasting 2 hours or more after topically applied menthol use, by product, participants who reported a cooling sensation (YES/ NO) and for the next question, participants reported duration of cooling assessed as follows:

1.Less than 10 minutes 2.10 minutes to less than 30 minutes 3.30 minutes to less than 60 minutes 4.60 minutes to less than 2 hours 5.2 hours to less than 3 hours 6.3 hours to less than 4 hours 7.4 hours or more
Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
Rating of Intensity from the use of topically applied menthol when used after the marathon
Zeitfenster: Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.

Average rating for intensity from the use of topically applied menthol when used after the marathon.

Intensity of cooling sensation is assessed post application of topically applied menthol, calculated using a 1-10 Rating Scale question to rate intensity of cooling sensation, where 1 is a mild cooling sensation, 10 is an extremely intense cooling sensation.
Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.
Rating of Intensity from the use of topically applied menthol when used during the marathon
Zeitfenster: Retrospective recall data from the end of race questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.

Average rating for intensity from the use of topically applied menthol when used during the marathon.

Intensity of cooling sensation is assessed post application of topically applied menthol, calculated using a 1-10 Rating Scale question on intensity of cooling sensation: scale 1-10, where 1 is a mild cooling sensation, 10 is an extremely intense cooling sensation.
Retrospective recall data from the end of race questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
Rating of Liking from the use of topically applied menthol when used after the marathon
Zeitfenster: Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.

Average rating for overall liking from the use of topically applied menthol when used after the marathon.

Overall liking of cooling sensation is assessed post application of topically applied menthol, calculated using a 1-10 Rating Scale question to rate overall liking of cooling sensation, where 1 is dislike extremely and 10 is like extremely.
Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.
Rating of Liking from the use of topically applied menthol when used during the marathon
Zeitfenster: Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.

Average rating for overall liking from the use of topically applied menthol when used during the marathon.

Overall liking of cooling sensation is assessed post application of topically applied menthol, calculated using a 1-10 Rating Scale question to rate overall liking of cooling sensation, where 1 is dislike extremely and 10 is like extremely.
Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
Percentage agreement that the cooling sensation from topically applied menthol helped to reduce pain.
Zeitfenster: Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.
Based on data collected in the Recovery Application Zone Questionnaire, the number of subjects who respond, "strongly agree" and "agree" to Likert Scale statement that the cooling sensation from topically applied menthol helped to reduce pain.
Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.
Proportion of participants agreement regarding statements about topically applied menthol
Zeitfenster: Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.

Participants who respond, "strongly agree" or "agree" to Likert Scale statements in the End of Race Questionnaire:

  1. Biofreeze relieves pain;
  2. The cooling sensation from Biofreeze reduces pain;
  3. Biofreeze use during the race helped me run/ walk over the finish line by relieving my pain.
Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
Percentage of participants experiencing pain relief lasting 2 hours or more after topically applied menthol
Zeitfenster: Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.

Based on retrospective recall data from the End of Race Questionnaire, participants who responded to a single-select question:

2 hours to less than 3 hours, 3 hours to less than 4 hours, 4 hours or more
Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
Analysis of Covariance (ANCOVA) model to assess association between age and pain outcomes (severity, location), and topically applied menthol use during the marathon
Zeitfenster: Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.

To assess impact of the following aspects on pain experience (pain severity and location and topically applied menthol use) during the marathon (based on retrospective recall data from the End of Race Questionnaire):

Age (self reported: ranges in years: 18-25; 26-35; 36-45; 46-55; 56-65; 66-75; 76 or older)

Pain Severity: (self-rated pain before use & immediately after Biofreeze use, both via Numeric Rating Scales 0-10 where 0 is no pain and 10 is the worst pain imaginable)

Pain Location (self-reported pain regions, e.g. pelvis; groin; knee; none of these)

Biofreeze Use:

  • whether it was used (yes/no)
  • type of Biofreeze product used (roll-on; base gel; professional gel; aerosol spray; patch)
  • when it was used (during the race; after the race in the recovery zone; after the race)
Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
Analysis of Covariance (ANCOVA) model to assess association between sex and pain outcomes (severity, location), and topically applied menthol use during the marathon
Zeitfenster: Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.

To assess impact of the following aspects on pain experience (pain severity and location and topically applied menthol use) during the marathon (based on retrospective recall data from the End of Race Questionnaire):

Sex (self reported: male; female; non-binary; prefer not to say) Pain Severity: (self-rated pain before use & immediately after Biofreeze use, both via Numeric Rating Scales 0-10 where 0 is no pain and 10 is the worst pain imaginable)

Pain Location (self-reported pain regions, e.g. pelvis; groin; knee; none of these)

Biofreeze Use:

  • whether it was used (yes/no)
  • type of Biofreeze product used (roll-on; base gel; professional gel; aerosol spray; patch)
  • when it was used (during the race; after the race in the recovery zone; after the race)
Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
Analysis of Covariance (ANCOVA) model to assess association between menstrual cycle stage, menopausal status and pain outcomes (severity, location), and topically applied menthol use during the marathon
Zeitfenster: Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.

To assess impact of the following aspects on pain experience (pain severity and location and topically applied menthol use) during the marathon (based on retrospective recall data from the End of Race Questionnaire):

Menstrual cycle stage and menopausal status (self-reported status; for example Have menstrual cycle, was on my period; Post menopausal)

Pain Severity: (self-rated pain before use & immediately after Biofreeze use, both via Numeric Rating Scales 0-10 where 0 is no pain and 10 is the worst pain imaginable)

Pain Location (self-reported pain regions, e.g. pelvis; groin; knee; none of these)

Biofreeze Use:

  • whether it was used (yes/no)
  • type of Biofreeze product used (roll-on; base gel; professional gel; aerosol spray; patch)
  • when it was used (during the race; after the race in the recovery zone; after the race)
Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
Analysis of Covariance (ANCOVA) model to assess association between amount of sleep, quality of sleep the night before the marathon and pain outcomes (severity, location), and topically applied menthol use during the marathon
Zeitfenster: Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.

To assess impact of the following aspects on pain experience (pain severity and location and topically applied menthol use) during the marathon (based on retrospective recall data from the End of Race Questionnaire):

Amount and quality of sleep the night before the marathon: (self reported: hours slept example: less than 1 hour, 2 hours to less than 3, 3 hours to less than 4, more than 8 hours; Sleep quality: very good; fairly good; fairly bad; very bad)

Pain Severity: (self-rated pain before use & immediately after Biofreeze use, both via Numeric Rating Scales 0-10 where 0 is no pain and 10 is the worst pain imaginable)

Pain Location (self-reported pain regions, e.g. pelvis; groin; knee; none of these)

Biofreeze Use:

  • whether it was used (yes/no)
  • type of Biofreeze product used (roll-on; base gel; professional gel; aerosol spray; patch)
  • when it was used (during the race; after the race in the recovery zone; after the race)
Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
Types of oral analgesic products used alongside topically applied menthol
Zeitfenster: Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
Participants reported types of oral analgesia used alongside topically applied menthol during the marathon and recovery period through the following question (option to select): Ibuprofen /Acetaminophen /Opioid /Naproxen /Aspirin / Combination Analgesic / Other.
Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
Number of participants who used analgesic products alongside topically applied menthol for pain relief during marathon
Zeitfenster: Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.

Types of oral analgesia used alongside topically applied menthol and number of participants who used each during the race and recovery period.

Participants reported use of oral analgesic products alongside topically applied menthol by single-select (YES/NO) question.
Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Reckitt Benckiser Healthcare (UK) Limited

Ermittler

  • Hauptermittler: Neeta Yousaf, PHD, Curion Strategic Product Insights

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

12. Oktober 2025

Primärer Abschluss (Tatsächlich)

12. Oktober 2025

Studienabschluss (Tatsächlich)

12. Oktober 2025

Studienanmeldedaten

Zuerst eingereicht

5. März 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

27. April 2026

Zuerst gepostet (Tatsächlich)

4. Mai 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

4. Mai 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

27. April 2026

Zuletzt verifiziert

1. April 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • 5106901

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

IPD is completely anonymised and each participant can no longer be identified.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Observational

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in United States

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

Abonnieren